ClinicalTrials.gg
CompletedNCT00254709Updated Jan 31, 2012

Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients

A Phase 4 interventional study of Sirolimus in Kidney Failure, Graft Rejection and Aged, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2012-01-31.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing sirolimus in Renal Insufficiency — none open to participants now, none under way, none of them phase 3. Sirolimus · Renal Insufficiency.

Enrollment
8th of 16
66 · median 63
Started
2002
with 1 other
Phase 4
6 of 16
none open now
Registered
7th of 16
by date
Lead sponsor
7 of 16
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 16 studies testing sirolimus in Renal Insufficiency, this one is the 8th largest by enrollment, is one of 2 that started in 2002, is one of 6 in phase 4, and was the 7th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 16 studies testing sirolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing sirolimus in Renal Insufficiency as a file.
02

Study summary

The purpose of this study is to test two different sirolimus-based immunosuppressive regimens for elderly kidney transplant recipients.

03

Conditions studied

  • Kidney Failure
  • Graft Rejection
  • Aged

Browse trials for

Keywords

  • kidney transplant
  • elderly
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • End stage renal disease
  • Kidney transplantation
  • Both donor and recipient older than 60 years

Exclusion criteria

Exclusion Criteria:

  • Prior or concurrent transplant of any organ other than the kidney
  • Current infections
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Renal function at 3 and 12 months; measured by Cockroft-Gault formula or serum creatinine

Secondary outcomes

  1. Incidence of acute rejections at 3 and 12 months

  2. Patient and graft survival at 3 and 12 months

  3. Incidence and duration of episodes of acute tubular necrosis

  4. Time to recover renal function (creatinine< 2 mg/dl)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2005
First posted
Nov 16, 2005
Start
Oct 2002
CompletionActual
Sep 2005
Last update
Jan 31, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00254709
Responsible party
Sponsor
First posted
Nov 16, 2005
Start date
Oct 2002
Completion
Sep 2005
Last update
Jan 31, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion